These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 38751556)

  • 21. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
    Bath NM; Pawlik TM
    Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DKK1 drives immune suppressive phenotypes in intrahepatic cholangiocarcinoma and can be targeted with anti-DKK1 therapeutic DKN-01.
    Jarman EJ; Horcas-Lopez M; Waddell SH; MacMaster S; Gournopanos K; Soong DYH; Musialik KI; Tsokkou P; Ng ME; Cambridge WA; Wilson DH; Kagey MH; Newman W; Pollard JW; Boulter L
    Liver Int; 2023 Jan; 43(1):208-220. PubMed ID: 35924447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of FGFR2 alterations in patients with iCCA undergoing surgery or systemic treatments: A meta-analysis.
    Niu S; Zhang Y; Li Z; Wang T
    Liver Int; 2024 Jun; ():. PubMed ID: 38829010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
    Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
    Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting FGFR inhibition in cholangiocarcinoma.
    Goyal L; Kongpetch S; Crolley VE; Bridgewater J
    Cancer Treat Rev; 2021 Apr; 95():102170. PubMed ID: 33735689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FGFR2 Inhibition in Cholangiocarcinoma.
    Vogel A; Segatto O; Stenzinger A; Saborowski A
    Annu Rev Med; 2023 Jan; 74():293-306. PubMed ID: 36170665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers.
    Lamarca A; Kapacee Z; Breeze M; Bell C; Belcher D; Staiger H; Taylor C; McNamara MG; Hubner RA; Valle JW
    J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
    Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
    Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
    Ko S; Kim M; Molina L; Sirica AE; Monga SP
    Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Any role for transarterial radioembolization in unresectable intrahepatic cholangiocarcinoma in the era of advanced systemic therapies?
    Elvevi A; Laffusa A; Elisei F; Morzenti S; Guerra L; Rovere A; Invernizzi P; Massironi S
    World J Hepatol; 2023 Dec; 15(12):1284-1293. PubMed ID: 38223418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
    Tang Z; Yang Y; Zhang Q; Liang T
    Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PARP inhibitor therapy in patients with IDH1 mutated cholangiocarcinoma.
    Mohan A; Quingalahua E; Gunchick V; Paul S; Kumar-Sinha C; Crysler O; Zalupski MM; Sahai V
    Oncologist; 2024 Jul; ():. PubMed ID: 39036962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular diagnosis of intrahepatic cholangiocarcinoma.
    Haga H; Patel T
    J Hepatobiliary Pancreat Sci; 2015 Feb; 22(2):114-23. PubMed ID: 25267595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma.
    Woodhead G; Lee S; Struycken L; Goldberg D; Hannallah J; Young S
    Life (Basel); 2024 Feb; 14(2):. PubMed ID: 38398726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive Immunogenomic Profiling of
    Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
    JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
    Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
    Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
    Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
    Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.